| INTRODUCTION
Crohn's disease is a chronic, relapsing-remitting inflammation of the intestinal tract. Inhibition of tumour necrosis factor-a (TNF) was shown to induce remission in patients with Crohn's disease. [1] [2] [3] [4] Certolizumab pegol is a recombinant, humanised, Fc-free, polyethylene glycol-conjugated antigen-binding fragment specific for human TNF, and is effective at reducing signs and symptoms of moderately to severely active Crohn's disease and maintaining clinical response in adult patients who have had an inadequate response to conventional therapy. 2, [4] [5] [6] Not all patients with Crohn's disease respond to treatment with TNF antagonists and both the time and the magnitude of response to therapy is variable. 4, 7, 8 Some variation has been associated with the development of antidrug antibodies (ADAb), which have been associated with increased clearance of drug, 9 but other disease-and patient-related factors also influence drug concentrations. 7 Factors that influence certolizumab pegol concentrations were examined in a population pharmacokinetic model for certolizumab pegol in patients with Crohn's disease. 10 The model, which used data from 2157 patients with Crohn's disease treated with certolizumab pegol in nine clinical trials, followed a conventional population pharmacokinetic model-building approach. Only baseline covariates were used, and thus individually predicted clearance remained constant over time. A refined population pharmacokinetic model was developed subsequently, 11 that takes into account the time-varying nature of patient characteristics and reduces the inter-patient variability of certolizumab pegol clearance estimates to < 20%, which is considered low for a biologic. The revised model also includes certolizumab pegol ADAb concentration as a continuous variable, allowing for evaluation of the concentration-dependent effect of ADAb on certolizumab pegol clearance. Other covariates that explained interpatient variability in apparent drug clearance were C-reactive protein, albumin, as well as other, less disease-related covariates such as body weight and gender. By taking into account the time-varying nature of these covariates, the refined population pharmacokinetic model constitutes an important improvement over the previous model, which is more reflective of patient drug exposure with sustained treatment, as patient and disease characteristics of patients with Crohn's disease are expected to change over time depending on their response to therapy. C87048 (NCT00329420) 6 and C87085 (NCT00552058) 14 ( Figure S1 ). All study protocols and consent forms were approved by institutional review boards or ethics committees at the study sites, and studies were conducted in accordance with the principles of good clinical practice and the Declaration of Helsinki. All patients provided written informed consent before study participation. ), because these were the only trials where faecal calprotectin data were recorded. Receiver operating characteristic analyses were carried out to determine optimal certolizumab pegol concentrations associated with efficacy outcomes during induction and maintenance. To maximise the sum of the specificity and sensitivity along the receiver operating characteristic curve, the Youden index was used to determine optimal certolizumab concentration thresholds.
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Certolizumab pegol concentration thresholds with high specificity (> 90%) were also evaluated.
Dropouts were considered as treatment failures for these analyses, regardless of the reason(s) for discontinuation. All authors had access to the study data, and reviewed and approved this manuscript for publication.
3 | RESULTS
| Baseline characteristics and outcomes to therapy
Data were collected from 2157 patients with Crohn's disease in nine studies. Of those, 2070 subjects received at least some form of certolizumab pegol induction therapy prior to week 6 and had a baseline value available for the efficacy outcome. The median age was 35 years, 56% were female, and 92% were white (Table S1 ). At week (33.7 vs 30.0 lg/mL; P < .001) relative to those who did not (Table 1 ).
The concentrations of certolizumab pegol were significantly higher in patients who achieved C-reactive protein ≤ 5 mg/L at week 6 relative to those who did not (week 2: 22.3 vs 19.1 lg/mL; week 4: 32.9 vs 26.8 lg/mL; week 6: 36.0 vs 27.2; all P < .001).
Similarly, certolizumab pegol concentrations were significantly higher in patients who achieved faecal calprotectin ≤ 250 lg/g at week 6
relative to those who did not (week 2: 22.9 vs 19.8 lg/mL; week 4: 34.9 vs 28.4 lg/mL; week 6: 38.6 vs 30.0 lg/mL; all P < .001). Also, for the composite endpoint of clinical remission (Crohn's disease activity index ≤ 150) and faecal calprotectin ≤ 250 lg/g at week 6, higher certolizumab pegol concentrations were observed in those who achieved the outcome vs those who did not at week 2 (22.1 vs 20.6; P = .003), week 4 (34.2 vs 30.3; P < .001) and week 6 (38.0 vs 32.0; P < .001) ( Table 1) .
Patients who achieved clinical response, clinical remission, Creactive protein ≤ 5 mg/L, or faecal calprotectin ≤ 250 lg/g had significantly higher medians for area under the concentration-time curve for certolizumab pegol from week 0 to week 6 than those who did not (P < .001 for all; Table 1 ). The differences in exposure were also explored graphically by comparing certolizumab pegol concentration-time curves (week 0-6 ) for the outcomes C-reactive protein ≤ 5 mg/L and faecal calprotectin ≤ 250 lg/g at week 6
( Figure 2 ). 
| Threshold analysis
Although the relationship between certolizumab pegol exposure and response varied among patients, certolizumab pegol concentration thresholds of at least 36.1 lg/mL and 14.8 lg/mL at week 6 and 12
(as defined by the Youden index), respectively, were associated with weeks 6 and 26 efficacy outcomes in receiver operating characteristic analyses (Table 3 and Figure S2 ). 
| DISCUSSION
This analysis originated from a large data set that was pooled from nine clinical trials of certolizumab pegol treatment for Crohn's T A B L E 1 Relationship between measures of certolizumab pegol exposure and various outcomes at week 6 and levels of C-reactive protein. 16 Furthermore, median concentrations of infliximab have also been associated with mucosal healing, 17 and higher trough concentrations of adalimumab were associated with clinical response to dose escalation. 18 In patients with ulcerative colitis, an exposure-response relationship was shown for infliximab and golimumab. 19, 20 Quartile analyses based on certolizumab pegol concentration The interaction between the log-transformed week 6 CZP and maintenance ADAb was statistically significant (P = .003).
T A B L E 3
Receiver operating characteristic analysis of weeks 6 and 12 certolizumab pegol concentrations and weeks 6 and 26 outcomes 23 In the present analyses, C-reactive protein and faecal calprotectin were included as efficacy outcomes and these biomarkers were significantly associated with certolizumab pegol concentrations. Interestingly, sensitivity analyses showed that varying the faecal calprotectin threshold (50 lg/g vs 175 lg/g vs 250 lg/g) did not significantly change the discriminatory power of certolizumab pegol concentrations (data not shown).
The robust composite outcome of Crohn's disease activity index ≤ 150 with faecal calprotectin ≤ 250 lg/g encompassed both clinical and endoscopic remission indicators, and was significantly associated with higher certolizumab pegol concentrations at both weeks 6 and 12. We recognise that a limitation of our study is that historic trials in Crohn's disease did not routinely assess endoscopic outcomes and thus these data were not available for analysis. However, a range of clinically important outcomes were evaluated, some of which are routinely used in clinical practice, and may improve the application of our results in real life.
The multivariable analysis showed that when patients were negative for ADAb to certolizumab pegol, drug concentrations at week 6
were significantly associated with the composite outcome at week 26.
Previously, the presence of ADAb has been associated with increased clearance of TNF antagonists, 10 increased incidence of adverse events 25 and with loss of response to treatment. 26 However, until now, it has been difficult to directly associate the presence or absence of ADAb with efficacy endpoints.
The receiver operating characteristic analyses showed moderate sensitivity and specificity for various certolizumab pegol concentration thresholds for the outcomes described here. Although the relationship between certolizumab pegol exposure and response varied among patients, approximate concentrations of at least 36 lg/mL and 15 lg/ mL certolizumab pegol at weeks 6 and 12 were associated with weeks 6 and 26 outcomes. Previously, receiver operating characteristic analyses of adalimumab exposure and response relationships revealed that higher concentrations of adalimumab were predictive of improvements in C-reactive protein and clinical remission, however, these relationships were not observed if the presence of ADAb was assessed. 27 Measurements of ADAbs may vary from one testing method to another, presenting a challenge for interpreting the data. Ligandbinding assays are the most common method of ADAb measurement. One such assay, ELISA, is used in these studies but it is susceptible to non-specific binding and false-positive findings. Several commercial assays for various anti-TNF antibodies are available. A new assay for measuring certolizumab pegol and certolizumab pegolADAb has recently been introduced, which may address some of these concerns (Miraca Life Sciences, Inc., Irving, TX, USA). 28, 29 One limitation of our study was the assay used to measure ADAb, which was drug sensitive and not able to detect ADAb in samples with detectable certolizumab pegol.
It has been proposed that therapeutic drug monitoring of TNF antagonists has the potential to be useful for predicting or preventing treatment failure in patients with Crohn's disease, and it may be helpful for deciding therapeutic interventions after primary loss of efficacy, 8 and to make treatment more cost-effective. 30 Knowledge of specific drug concentration thresholds that correspond with efficacy outcomes, as identified in this analysis, may inform therapeutic drug monitoring and guide decisions in clinical practice.
Overall, these results suggest that achieving higher concentrations of certolizumab pegol during induction and maintenance therapy may improve biological and clinical response. The large size of this data set and the multiple analytical approaches constitute an important improvement over previous exposure-response analyses. 14, 16, 31 These results now need to be corroborated in a prospective, interventional study including endoscopic outcomes that will test the approach of dosing based on drug exposure, by using the described population pharmacokinetic model to calculate, in individual patients, the exact dose needed to achieve the proposed certolizumab pegol concentration thresholds.
